Please use this identifier to cite or link to this item: https://doi.org/10.1186/s13045-015-0163-z
DC FieldValue
dc.titleStage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: A clinicopathologic analysis of 61 patients
dc.contributor.authorLoghavi, S
dc.contributor.authorAlayed, K
dc.contributor.authorAladily, T.N
dc.contributor.authorZuo, Z
dc.contributor.authorNg, S.-B
dc.contributor.authorTang, G
dc.contributor.authorHu, S
dc.contributor.authorYin, C.C
dc.contributor.authorMiranda, R.N
dc.contributor.authorMedeiros, L.J
dc.contributor.authorKhoury, J.D
dc.date.accessioned2020-10-27T05:40:21Z
dc.date.available2020-10-27T05:40:21Z
dc.date.issued2015
dc.identifier.citationLoghavi, S, Alayed, K, Aladily, T.N, Zuo, Z, Ng, S.-B, Tang, G, Hu, S, Yin, C.C, Miranda, R.N, Medeiros, L.J, Khoury, J.D (2015). Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: A clinicopathologic analysis of 61 patients. Journal of Hematology and Oncology 8 (1) : 65. ScholarBank@NUS Repository. https://doi.org/10.1186/s13045-015-0163-z
dc.identifier.issn17568722
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/180909
dc.description.abstractBackground: Plasmablastic lymphoma (PBL) is a rare aggressive neoplasm with lymphoid and plasmacytic differentiation that is commonly associated with immunodeficiency and an unfavorable prognosis. Clinicopathologic features have been largely derived from cases reports and small series with limited outcome analyses. Patients and methods: The demographic, clinicopathologic features, and clinical outcomes of a cohort of 61 patients with PBL were reviewed and analyzed. Results: Patients had a median age of 49 years (range 21-83 years) and most (49/61; 80 %) were men. Human immunodeficiency virus (HIV) status was available for 50 patients: 20 were HIV-positive and 30 HIV-negative. Twenty-three patients were immunocompetent. Abdominal/gastrointestinal complaints were the most common presenting symptoms, reported in 14 of 47 (30 %) of patients. At presentation, 24 of 43 (56 %) patients had stage III or IV disease. Epstein-Barr virus (EBV) was detected in 40 of 57 (70 %) cases. MYC rearrangement was identified in 10/15 (67 %) cases assessed, and MYC overexpression was seen in all cases assessed regardless of MYC rearrangement status. HIV-positive patients were significantly younger than those who were HIV-negative (median 42 vs. 58 years; p∈=∈0.006). HIV-positive patients were also significantly more likely to have EBV-positive disease compared with HIV-negative patients (19/19, 100 % vs. 15/29, 52 %; p∈=∈0.002). Patients who received CHOP chemotherapy tended to have better overall survival (OS) compared with those who received hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) (p∈=∈0.078). HIV status had no impact on OS. Patients with EBV-positive PBL had a better event-free survival (EFS) (p∈=∈0.047) but not OS (p∈=∈0.306). Notably, OS was adversely impacted by age ge;50 years (p∈=∈0.013), stage III or IV disease (p∈=∈<0.001), and lymph node involvement (p∈=∈0.008). Conclusions: The most significant prognostic parameters in patients with PBL are age, stage, and, to a lesser extent, EBV status. In this study, two-thirds of PBL cases assessed were associated with MYC rearrangement and all showed MYC overexpression. © 2015 Loghavi et al.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectcyclophosphamide
dc.subjectdexamethasone
dc.subjectdoxorubicin
dc.subjectetoposide
dc.subjectprednisone
dc.subjectvincristine
dc.subjectantineoplastic agent
dc.subjectabdominal pain
dc.subjectadult
dc.subjectage distribution
dc.subjectaged
dc.subjectArticle
dc.subjectcancer chemotherapy
dc.subjectcancer prognosis
dc.subjectcancer staging
dc.subjectcancer survival
dc.subjectcarcinogenesis
dc.subjectclinical evaluation
dc.subjectcohort analysis
dc.subjectcolorimetry
dc.subjectcontrolled study
dc.subjectcorrelational study
dc.subjectcytogenetics
dc.subjectdiarrhea
dc.subjectepistaxis
dc.subjectEpstein Barr virus
dc.subjectEpstein Barr virus infection
dc.subjectevent free survival
dc.subjectfemale
dc.subjectfluorescence in situ hybridization
dc.subjectfollow up
dc.subjectgastrointestinal symptom
dc.subjectgene overexpression
dc.subjectgene rearrangement
dc.subjecthealth impact assessment
dc.subjecthistopathology
dc.subjecthuman
dc.subjectHuman immunodeficiency virus infection
dc.subjecthuman tissue
dc.subjectimmunocompromised patient
dc.subjectimmunophenotyping
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectnose ulcer
dc.subjectoncogene myc
dc.subjectoutcome assessment
dc.subjectoverall survival
dc.subjectplasmablastic lymphoma
dc.subjectrectum hemorrhage
dc.subjectrhinorrhea
dc.subjectsinusitis
dc.subjectvery elderly
dc.subjectvirus detection
dc.subjectage
dc.subjectcancer staging
dc.subjectcomplication
dc.subjectEpstein Barr virus infection
dc.subjectgenetics
dc.subjectmiddle aged
dc.subjectpathology
dc.subjectplasmablastic lymphoma
dc.subjecttreatment outcome
dc.subjectyoung adult
dc.subjectAdult
dc.subjectAge Factors
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectCohort Studies
dc.subjectEpstein-Barr Virus Infections
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNeoplasm Staging
dc.subjectPlasmablastic Lymphoma
dc.subjectTreatment Outcome
dc.subjectYoung Adult
dc.typeArticle
dc.contributor.departmentPATHOLOGY
dc.description.doi10.1186/s13045-015-0163-z
dc.description.sourcetitleJournal of Hematology and Oncology
dc.description.volume8
dc.description.issue1
dc.description.page65
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_s13045-015-0163-z.pdf2.03 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons